$CRL News

Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $260

3 Reasons to Avoid CRL and 1 Stock to Buy Instead

Is This the Right Time to Hold CRL Stock in Your Portfolio?

Is Charles River Laboratories International, Inc. (CRL) A Good Stock To Buy Now?

How Is Charles River Laboratories’ Stock Performance Compared to Other Health Care Stocks?

Morgan Stanley Upgrades Charles River Laboratories International (CRL)

Morgan Stanley Upgrades Charles River to Overweight, Raises Price Target to $220

Charles River Labs (CRL) Pulled Back Due to AI Disruption Fears

Assessing Charles River Laboratories (CRL) Valuation After Mixed Returns And Contrasting Undervaluation Signals

Charles River Laboratories International, Inc. (CRL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Charles River Laboratories International, Inc. (CRL) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow

Charles River Laboratories International, Inc. (CRL) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Charles River Laboratories to Present at William Blair and Jefferies Conferences

CLSA Upgrades Charles River Laboratories International (CRL)

CLSA Upgrades Charles River to Outperform, Raises Price Target to $219

Are Wall Street Analysts Bullish on Charles River Laboratories Stock?

Is Charles River (CRL) Quietly Recasting Its Moat Around AI Pathology And Cell Therapy Services?

Charles River Laboratories (CRL) is a Top-Ranked Value Stock: Should You Buy?

Drug Development Inputs & Services Stocks Q1 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers

The 5 Most Interesting Analyst Questions From Charles River Laboratories’s Q1 Earnings Call